Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MGI, Eisai deal

Eisai will acquire MOGN for $41 per share, or about $3.9 billion, in cash. The price is a 23% premium to MOGN's close

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE